Neural Respiratory Drive Combined With Pro-Brain Natriuretic Peptide (Pro-BNP) as Predictor of Deterioration After Lung Transplantation

April 6, 2026 updated by: Zhang Jianheng, The First Affiliated Hospital of Guangzhou Medical University

Lung transplantation has become a promising therapeutic option for various end-stage lung diseases. However, many factors such as infection, graft rejection, airway complications would cause deterioration and shorten the survival time. It is important to detect the deterioration early and receive treatment timely, which may enhance survival.

We hypothesis the decreased neural respiratory drive(NRD) would be increased in the deterioration due to the aggravation of lung. Furthermore, pro-Brain Natriuretic Peptide(pro-BNP) has been reported to be associated with greater mortality after lung transplantation.For this reason, we investigated the NRD and pro-BNP before and after lung transplantation and during deterioration.

80 patients were recruited.They were end-stage lung disease patients admitted to hospital for lung transplantation. The NRD and pro-BNP were monitored before and after lung transplantation.we investigated the NRD and pro-BNP before and after lung transplantation and during deterioration.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Guangzhou, China, 520120

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The patients with end-stage lung diseases referral to lung transplantation. Including chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasia

Description

Inclusion Criteria:

The patients with end-stage lung diseases referral to lung transplantation,Including chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasia

Exclusion Criteria:

(1) Malignancy （2）Severe cardiovascular diseases （3）Neuromuscular and chest wall deformity (4) Cardiovascular instability (hypotension, arrhythmias, myocardial infarction) (5) Change in mental status; uncooperative patients （6）Renal failure and severe blood electrolyte disturbances

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
the patients with end-stage lung diseases after lung transplantation
we investigated the NRD and pro-BNP before and after the patients with end-stage lung diseases lung transplantation and during deterioration. The relationship between NRD and pro-BNP and the deterioration were investigated
Other: No Intervention: Observational Cohort
no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
deterioration
Time Frame: 6 years
deterioration rate
6 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The First Affiliated Hospital of Guangzhou Medical University

Investigators

  • Principal Investigator: jianheng zhang, MD, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2016

Primary Completion (Actual)

February 1, 2026

Study Completion (Actual)

February 1, 2026

Study Registration Dates

First Submitted

April 6, 2026

First Submitted That Met QC Criteria

April 6, 2026

First Posted (Actual)

April 13, 2026

Study Record Updates

Last Update Posted (Actual)

April 13, 2026

Last Update Submitted That Met QC Criteria

April 6, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • YLS2024
  • 2020B11111340009 (Other Grant/Funding Number: Zhong nan shan medical foundation of Guangdong province)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

The data is being analyzed.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Transplantation

Clinical Trials on No Intervention: Observational Cohort

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe